RAD - Rite Aid Corporation

NYSE - NYSE Delayed Price. Currency in USD
6.86
-0.20 (-2.83%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close7.06
Open7.06
Bid6.79 x 800
Ask7.65 x 1400
Day's Range6.77 - 7.10
52 Week Range6.73 - 42.40
Volume1,702,635
Avg. Volume1,668,864
Market Cap368.919M
Beta (3Y Monthly)1.70
PE Ratio (TTM)N/A
EPS (TTM)-7.99
Earnings DateJun 26, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1999-10-14
1y Target Est9.00
Trade prices are not sourced from all markets
  • Business Wire19 hours ago

    Rite Aid Partners with Adobe to Drive Digital Transformation

    Adobe Experience Cloud to Power Rite Aid’s Seamless, Personalized Customer Health and Wellness Experience

  • Business Wire20 hours ago

    Rite Aid to Release First Quarter Results on June 26

    Rite Aid Corporation said today that it will release financial results for its Fiscal 2020 First Quarter, which ended June 1, 2019, on Wednesday, June 26, 2019. The company will hold an analyst call at 5:00 p.m.

  • This National Grocery Chain Will Carry CBD in 17 States
    Motley Fool5 days ago

    This National Grocery Chain Will Carry CBD in 17 States

    With more than 2,700 branded locations nationwide, this grocer plans to introduce topical CBD products in a third of all states.

  • Moody's6 days ago

    Rite Aid Corporation -- Moody's announces completion of a periodic review of ratings of Rite Aid Corporation

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Rite Aid Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Benzinga6 days ago

    Jim Cramer Shares His Thoughts On TherapeuticsMD, Rite Aid And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said he likes Yeti Holdings Inc (NYSE: YETI ) very much. He believes the stock is undervalued and he sees it as a long-time hold. Daktronics, ...

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Rite Aid Corp.

    Rite Aid Corp NYSE:RADView full report here! Summary * Perception of the company's creditworthiness is negative and weakening * Bearish sentiment is high * Economic output in this company's sector is contracting Bearish sentimentShort interest | NegativeShort interest is extremely high for RAD with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting RAD. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold RAD had net inflows of $2.01 billion over the last one-month. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers’ Index (PMI) data, output in the Consumer Servicesis falling. The rate of decline is significant relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator with a weakening bias over the past 1-month. RAD credit default swap spreads are at their highest levels for the past 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • New owner comes into play at one of the city's busiest corners
    American City Business Journals15 days ago

    New owner comes into play at one of the city's busiest corners

    Freilich and California partner pay more than $200 a square foot for Forbes and Murray building that's home to tech firms IBM and M Modal

  • Moody's18 days ago

    J.P. Morgan Chase Commercial Mortgage Securities Corp. Series 2003-CIBC6 -- Moody's upgrades two and affirms three classes of JPMC 2003-CIBC6

    For ratings issued on a support provider, this announcement provides certain regulatory disclosures in relation to the credit rating action on the support provider and in relation to each particular credit rating action for securities that derive their credit ratings from the support provider's credit rating. For any affected securities or rated entities receiving direct credit support from the primary entity(ies) of this credit rating action, and whose ratings may change as a result of this credit rating action, the associated regulatory disclosures will be those of the guarantor entity. Regulatory disclosures contained in this press release apply to the credit rating and, if applicable, the related rating outlook or rating review.

  • Business Wire19 days ago

    Erik Keptner Named Rite Aid Chief Marketing and Merchandising Officer

    Rite Aid Corporation (RAD) announced today that Erik Keptner, a proven leader with more than 20 years’ experience in retail marketing, has been named to the newly created position of senior vice president and chief marketing and merchandising officer, effective June 24, 2019. In this position, Keptner will be responsible for all aspects of marketing and merchandising. “Erik is an experienced retail executive who has proven that he can integrate and manage all aspects of an organization’s marketing and merchandising assets to provide great customer experiences, operate efficiently and deliver growth,” said Everett.

  • Business Wire21 days ago

    The Rite Aid Foundation Announces Additional $6 Million Commitment to Folds of Honor

    Over the Memorial Day weekend, The Rite Aid Foundation announced a three-year, $6 million commitment to Folds of Honor, a nonprofit organization that provides educational scholarships to children of military service members who have been killed or seriously wounded while serving our country. This is The Rite Aid Foundation’s third contribution to Folds of Honor. Since 2015, The Foundation has awarded more than $13 million to the organization, including $1.3 million in 2015 and another three-year, $6 million commitment in 2016.

  • A Reverse Stock Split Won't Save Blue Apron
    Motley Fool28 days ago

    A Reverse Stock Split Won't Save Blue Apron

    With a 1-to-5 or more likely 1-for-15 split on the horizon, the meal-kit pioneer will have a hard time cooking up a turnaround.

  • Morningstarlast month

    Walgreens' Prescription for Growth

    Founded in 1901,  Walgreens Boots Alliance WBA is the leading pharmacy retailer, leveraging its scale to provide convenience. The company generates nearly $140 billion in revenue and dispenses over 1 billion prescriptions annually, representing one fourth of the drug market. Scale remains critical in an increasingly competitive market that has witnessed some rationalization of subscale peers.

  • Business Wirelast month

    Measles-Mumps-Rubella Vaccine Available at Rite Aid Pharmacies in Maryland

    With the highest rate of measles cases being reported in the United States since the disease was declared eliminated in 2000, Rite Aid announced today that Measles-Mumps-Rubella (MMR) vaccinations are available upon request at Rite Aid pharmacies across Maryland. No appointment is necessary and vaccinations from a Rite Aid certified immunizing pharmacist are available during normal pharmacy business hours. There are currently five confirmed cases of measles, in Maryland, as well numerous sites that have been identified for potential exposure according to the Maryland Department of Health.

  • Rite Aid (RAD) Outpaces Stock Market Gains: What You Should Know
    Zackslast month

    Rite Aid (RAD) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Rite Aid (RAD) closed at $8.93, marking a +1.59% move from the previous day.

  • Business Wirelast month

    Rite Aid Expands Availability of Thrifty Ice Cream to Pacific Northwest

    Thrifty Ice Cream Now Available in Idaho, Oregon and Washington in 48-ounce Containers and Up to Eight Flavors

  • Rite Aid (RAD) Down 22.3% Since Last Earnings Report: Can It Rebound?
    Zackslast month

    Rite Aid (RAD) Down 22.3% Since Last Earnings Report: Can It Rebound?

    Rite Aid (RAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Why Rite Aid Stock Plummeted 27.9% in April
    Motley Foollast month

    Why Rite Aid Stock Plummeted 27.9% in April

    The market was none too pleased about the pharmacy retail chain's progress last quarter.

  • CVS Stock Might Look Cheap, but It Is a Value Trap
    InvestorPlacelast month

    CVS Stock Might Look Cheap, but It Is a Value Trap

    If you follow social media, you'll see a ton of people calling CVS Health (NYSE:CVS) a compelling bargain right now. The stock sells for just over book value, 7.6x forward earnings, and offers a more than 3.5% dividend yield. For investors in the Peter Lynch "buy what you know" school of investing, CVS stock seems appealing. A respected company with omnipresent stores across the country selling at a deeply discounted valuation. So what's not to like?Source: Mike Mozart via FlickrThere are a few reasons for caution on CVS stock, despite the apparent positives. For one, the company has become far more than a pharmacy chain. And in its numerous acquisitions, it has loaded the company up with debt and risk.For another, the company's profit margins are under fire on many sides. The stock market isn't being unreasonable in pricing CVS stock for a series of difficult years ahead.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Great Stocks to Buy on Dips Dangerous Empire-BuildingI was never a fan of CVS' move into the pharmacy benefit manager (PBM) space. It may feel quite closely related to the main business; a PBM manages prescription benefits for self-insured companies, government organizations and other such entities that don't use a major health insurance operator. CVS could certainly achieve cost savings by fusing these two operations together, right?In practice, though, they are quite separate businesses. Dealing with private companies and Medicare is much different than running its pharmacies and walk-in clinics. As it would so happen, both retail pharmacy and PBMs have been struggling over the past few years, so CVS' diversification did little to alter its trajectory as compared with Walgreens Boots Alliance (NYSE:WBA).That said, CVS recently went all-in on becoming a one-stop health care destination. It made a gigantic $68 billion deal for health insurer Aetna. This was reportedly a defensive move, as Aetna itself was a major client of CVS' PBM. Buying them kept that business in-house rather than risking defection; it also took one major M&A target off the market. This was viewed as an important move to try to keep Amazon (NASDAQ:AMZN) from potentially entering the industry.Now, with the Aetna deal closed, CVS controls a significant chunk of the whole health care supply chain, from a walk-in flu shot on up through drug dispensing, Medicare management, and private health insurance. Deals Don't Inspire ConfidenceUnfortunately, this health care colossus faces a number of challenges. For one, management is showing questionable judgment. Its $12.7 billion acquisition of Omnicare in 2015 has already led to more than $6 billion in write-offs. CVS both misread that market in long-term care and also overestimated how many synergies there would be in the deal.This is problematic, since a large number of analysts believe CVS overpaid for Aetna. They offered a sizable premium to a stock that was already trading at all-time highs and was up exponentially heading into the deal. Aetna stock traded in the $20s a decade ago; CVS paid more than $200 per share.Interestingly, between 1977 and 2000, Aetna stock created only modest value for its shareholders. In a normal health care market, a health insurance firm should not spike in value nearly 10-fold inside of a decade. If you want to see why health care costs are soaring, the PBMs and the health insurers are a great place to look. Political Risk LoomsRecently, we've see a huge blame the other person game going on with health care costs. The drug companies say prescription pills are expensive because the PBMs and health insurers are overcharging everyone, taking way too much of a cut as middlemen. The health insurers are blaming the PBMs for overcharging them. The PBMs, in turn, have been blaming the pharmacies.This has been a profitable game for the past decade, everyone inflating costs while blaming someone else, but it won't and can't go on much longer. The health care system is simply too expensive for this sort of activity to drag on indefinitely.CVS is again promising huge synergies with the Aetna deal, but they won't get them. CVS is essentially competing against itself here in a way, as you have the entities that were all sticking each other with excessive costs now under one roof. With only CVS standing between the pharmaceutical company and the end patient, it will be far harder for CVS to wring so-called excessive profits out of this system.You see analysts expecting profit margins (which are already trending well downward) to continue dropping for both retail pharmacy and PBMs. Perhaps CVS felt compelled to buy Aetna as the health insurers are still doing better for the time being. These sorts of gains can't keep up if Medicare is going to remain solvent. Unfortunately for CVS, they top-ticked the market buying Aetna for an absurd price.Already shares of other health insurers have plummeted this year, with UnitedHealth (NYSE:UNH) and Humana (NYSE:HUM) both dropping around 30% since December.This fall has coincided with the rise of anti-private health insurance candidates such as Bernie Sanders for the 2020 presidential election. Health insurance costs will be a major campaign issue, and CVS has launched itself into the crossfire by paying up for Aetna. CVS Stock VerdictAs I mentioned, it's easy to make a case that CVS stock is cheap on valuation. However, there are several things to take into account before hitting the buy button. For one, CVS has a huge debt load post-Aetna, with its $70 billion debt just about equal to the company's market cap. The company's earnings will need to be channeled in large part to managing its debt rather than dividend hikes or share buybacks for the time being.Additionally, nearly all segments of the business are struggling. Retail pharmacy has issues, as results from Walgreens and Rite Aid (NYSE:RAD) have confirmed. PBMs have been weak in recent years, and now Aetna is at risk as the politicians threaten to regulate profits from that sector sharply lower or outlaw big chunks of the business entirely.Finally, CVS' management has not shown good discipline in dealmaking, first with the disastrous Omnicare deal and now this most questionable Aetna one. With the health care industry passing through such trying times, CVS stock is an easy avoid for the time being.At the time of this writing, Ian Bezek owned WBA stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Great Stocks to Buy on Dips * 6 Growth Stocks to Buy for the Rest of 2019 * 4 Mega-Cap Stocks to Sell Before They Melt Down Compare Brokers The post CVS Stock Might Look Cheap, but It Is a Value Trap appeared first on InvestorPlace.

  • Rite Aid (RAD) Dips More Than Broader Markets: What You Should Know
    Zackslast month

    Rite Aid (RAD) Dips More Than Broader Markets: What You Should Know

    Rite Aid (RAD) closed the most recent trading day at $8.08, moving -0.62% from the previous trading session.

  • Bear Of The Day: Rite Aid (RAD)
    Zackslast month

    Bear Of The Day: Rite Aid (RAD)

    Bear Of The Day: Rite Aid (RAD)

  • CNBClast month

    Walmart raises minimum age to buy tobacco to 21 as pressure mounts to curb illegal sales to minors

    Walmart outlined steps to prevent minors from buying tobacco products in a letter to the FDA.

  • Lockheed Martin, Rite Aid, Avid Technology, NeoPhotonics and EXFO highlighted as Zacks Bull and Bear of the Day
    Zackslast month

    Lockheed Martin, Rite Aid, Avid Technology, NeoPhotonics and EXFO highlighted as Zacks Bull and Bear of the Day

    Lockheed Martin, Rite Aid, Avid Technology, NeoPhotonics and EXFO highlighted as Zacks Bull and Bear of the Day

  • Business Wirelast month

    Rite Aid Recognizes Six Pharmacy Team Members For Outstanding Service Through Its Annual Pharmacy Champions Program

    Six members of Rite Aid’s pharmacy team have been selected for recognition through the company’s annual Pharmacy Champions program. This year, Rite Aid associates selected as the company’s “Pharmacy Champions” will each receive $2,500 in Rite Aid gift cards and the ability to designate a KidCents charity to receive a $2,500 donation from The Rite Aid Foundation. The six customers who nominated those selected will each receive $2,500 in Rite Aid gift cards.